ArticleFrontiers in cardiovascular medicine2025
Influencing factors analysis of clinical effect of heart failure patients treated with ivabradine and metoprolol succinate and construction and validation of nomogram prediction model.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the influencing factors of the clinical effect of ivabradine (Ivab) combined with metoprolol succinate (Met-S) in patients with heart failure (HF), and to construct and verify the nomogram prediction model, in order to provide reference for clinical treatment. Methods: 250 cases of HF patients from January 2021 to June 2023 were selected. The relevant factors affecting the therapeutic effect were screened out through univariate and multivariate analysis. The nomogram prediction model was constructed, and the model was verified and evaluated using receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA). Results: Single factor and multiple factor analyses showed that LVEF, LVEDD, 6 MWT, heart rate and BNP level were the independent risk factors for clinical effects ( Conclusion: LVEF, LVEDD, 6 MWT, heart rate and BNP level affect the clinical effect of Ivab combined with Met-S in patients with HF. The nomogram prediction model established has high accuracy and clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.